Two sports medicine physicians at the Performance Medicine Institute in Phoenix walk through eleven peptides that are either FDA approved for narrow indications or sold direct to consumers as unregulated “research chemicals,” including BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, GHK-Cu, follistatin-344, and the two approved growth hormone secretagogues sermorelin and tesamorelin. The authors compare what the marketing claims against what has actually been tested in humans, and conclude that for most of the gray market compounds, the evidence base ranges from thin to nonexistent, while the physiological plausibility for real harm, including cancer-related concerns for BPC-157 and thymosin beta-4, is not trivial. A substantial portion of the paper is devoted to explaining why people feel better anyway: placebo and contextual effects, amplified by social media rituals and influencer endorsement.
Walk into any biohacking forum and you will find people injecting themselves with peptides that have never been tested in a single human clinical trial. BPC-157, TB-500, CJC-1295: these names circulate with the confidence of established medicine, but a new review in the journal Sports Medicine pulls back the curtain, and the picture is less reassuring than the marketing suggests.
The authors, Christopher Mendias and Tariq Awan, split the peptide world into two camps. On one side sit drugs like tesamorelin and sermorelin, which went through actual clinical trials, thousands of subjects, and FDA review. On the other side sits a “gray market” of compounds sold with labels reading “not for human consumption,” a legal loophole that lets vendors dodge regulation while marketing directly to patients through social media. The review finds that popularity and evidence are almost inversely related. The peptides generating the most Google searches since 2024, BPC-157 and TB-500 among them, are precisely the ones with the least human safety data.
The stakes are not abstract. BPC-157 works partly by boosting a growth factor called VEGF, which helps tissue heal, but the same signaling pathway is a well-known driver of tumor growth and metastasis. Thymosin beta-4, the parent molecule of TB-500, is elevated in several aggressive cancers. CJC-1295, a growth hormone booster, caused adverse events in 94 percent of trial participants versus 29 percent on placebo, and a related trial was halted after a patient death. None of this stops the gray market. Peptides are manufactured outside any quality control system, meaning a “99 percent pure” vial can still be contaminated with heavy metals, endotoxins, or simply the wrong molecule.
So why do so many people swear these injections work? The review’s most interesting contribution may be its account of the placebo and contextual effect, which is not “just in your head” but a real neurobiological phenomenon involving opioid and dopamine signaling in the brain, amplified enormously by the ritual of injection, the endorsement of a trusted influencer, and the psychological investment of paying for something new. Social media, the authors argue, has become an engine for manufacturing exactly the conditions under which contextual effects thrive, creating a feedback loop that pulls people toward trying one peptide after another. The paper closes with a practical framework for clinicians and a blunt message: real answers require real trials, not testimonials.
Actionable Insights
The clearest, quantified benefits in this review belong to the two FDA approved growth hormone secretagogues, not the gray market compounds people are actually searching for online. Tesamorelin, given for six to twelve months, produced measurable but modest body composition changes: roughly 8 to 15 percent reductions in visceral fat and 1.4 to 2.2 percent increases in lean mass, in specific patient populations (HIV associated lipodystrophy, or obesity with reduced growth hormone secretion), not healthy athletes. A comparable GHRH analog increased lean mass by 2.3 percent over five months. These are real but modest numbers, not transformative ones.
For the popular gray market peptides, BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, the honest effect size for musculoskeletal healing or performance in humans is currently undefined, because no adequately controlled human trials exist. The one quantified risk figure in the review is stark: CJC-1295 caused adverse events in 94 percent of treated subjects versus 29 percent on placebo, a more than threefold relative risk. The take-home message is that the magnitude of proven benefit and the magnitude of documented risk are wildly asymmetric for most peptides currently being marketed to biohackers.
Overall Take
The probabilistic read here is straightforward. For FDA approved peptides used within their studied indications, sermorelin, tesamorelin, and SS-31, the evidence strongly supports real, modest, mechanistically grounded benefit with a known and acceptable safety profile. For the gray market peptides driving most of the current biohacker interest, BPC-157, TB-500, CJC-1295, MOTS-c, ipamorelin, and injectable GHK-Cu, the honest current answer is that efficacy in humans is unproven, safety data ranges from thin to actively concerning, and a meaningful fraction of any perceived benefit is plausibly attributable to placebo and social contextual effects rather than pharmacology.
Context and Source
- Paywalled Paper: Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
- Authors: Christopher L. Mendias and Tariq M. Awan.
- Institution: Performance Medicine Institute, Phoenix, Arizona, USA (a private clinical/research practice, not a university-affiliated center).
- Country: United States.
- Journal: Sports Medicine (Springer Nature), accepted 24 March 2026.
- Journal Impact Evaluation: Sports Medicine carries a 2025 Journal Impact Factor of approximately 11.0 (5-year JIF approximately 13.7) and a Scopus CiteScore of approximately 19.8, and is ranked JCR Q1, effectively the number one ranked title in the Sports Sciences category. Therefore this is a High to Elite impact journal within its specialty niche.
Related Reading:
- ‘I wouldn’t dare take these drugs’: how China supplies untested peptides to the west (Financial Times)
- Finnrick Peptide Quality and Test Ratings Explained
- Peter Magic, the founder of Janoshik, Peptide Testing
- Peptides / Bioregulators
- MIT Tech Review: Peptides are everywhere. Here’s what you need to know